Fulcrum Therapeutics operates as a clinical-stage biopharmaceutical enterprise focused on discovering and developing small-molecule therapeutics for genetically defined rare diseases. Within the competitive biotechnology landscape, its primary competitors include other genomic medicine firms, rare disease drug developers, and clinical-stage biopharmaceutical companies specializing in gene modulation, epigenetic therapies, and targeted treatments for conditions like sickle cell disease and facioscapulohumeral muscular dystrophy.